← Back to Search

Plasma Volume Expander

Hydroxyethylstarch 130/0.4 for Low Blood Pressure

Phase 4
Waitlist Available
Led By Christian Loubert, MD, FRCPC
Research Sponsored by Maisonneuve-Rosemont Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The purpose of this trial is to determine the effective volume of hydroxyethylstarch 130/0.4 which would prevent the occurence of maternal hypotension in 50% of healthy pregnant women undergoing a cesarean section under spinal anesthesia.

Eligible Conditions
  • Low Blood Pressure
  • Fluid Therapy
  • Obstetric Anesthesia
  • Cesarean Section
  • Spinal Anesthesia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2019 Phase 4 trial • 160 Patients • NCT03350217
16%
Intraprocedural Bleeding
1%
Delayed Bleed
1%
Abdominal Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Hetastarch
Eleview

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hydroxyethylstarch 130/0.4Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Maisonneuve-Rosemont HospitalLead Sponsor
101 Previous Clinical Trials
38,313 Total Patients Enrolled
Université de MontréalOTHER
219 Previous Clinical Trials
103,112 Total Patients Enrolled
Christian Loubert, MD, FRCPCPrincipal InvestigatorMaisonneuve-Rosemont Hospital
2 Previous Clinical Trials
60 Total Patients Enrolled
~2 spots leftby Sep 2025